GM Statement

RNS Number : 1560U

MGC Pharmaceuticals Limited

31 March 2021

 

31 March 2021 ASX Code: MXC LSE Code: MXC

Results of General Meeting

MGC Pharmaceuticals Ltd (ASX: MXC, 'MGC Pharma' or 'the Company'), would like to confirm the results of the Company's General Meeting held 31 March 2021. All resolutions put to the meeting were passed on a poll. Details of the proxy and poll voting on the resolutions are set out in the attached report. http://www.rns-pdf.londonstockexchange.com/rns/1560U_1-2021-3-31.pdf --Ends-- Authorised for issue by Narelle Warren, Company Secretary, further information, please contact: PR/IR Advisors - Media & Capital Partners Rod Hinchcliffe (IR) [phone] [e-mail] MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director [phone] [e-mail]   UK Broker - Turner Pope Andy Thacker [e-mail] Zoe Alexander [phone] [e-mail] UK PR Advisors - Tavistock Charles Vivian [phone] [e-mail] Tim Pearson [phone] [e-mail]

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally.  The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline. 

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.  

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. 

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

 

END

 

 

GMSDKDBQDBKDFNN